License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details) - Cyclerion Therapeutics License Agreement $ in Millions	Jun. 04, 2021 USD ($)
Asset Acquisition [Line Items]
Upfront payment for asset acquisition	$ 3.0
Contingent consideration from developmental and regulatory milestones	$ 222.0

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration